Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control

The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV

(2014) E. R. Hammond et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

(2013) Matteo Vassallo et al.   AIDS

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

(2013) Nicoletta Ciccarelli et al.   ANTIVIRAL THERAPY

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

(2013) A. Calcagno et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Etravirine in CSF is highly protein bound

(2013) A. Nguyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-associated neurocognitive disorder

(2013) David B Clifford et al.   LANCET INFECTIOUS DISEASES

HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naïve Patients

(2013) Victor G. Valcour et al.   PLoS One

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

(2012) Michael J. Peluso et al.   AIDS

Determinants of darunavir cerebrospinal fluid concentrations

(2012) Andrea Calcagno et al.   AIDS

Novel Method To Assess Antiretroviral Target Trough Concentrations UsingIn VitroSusceptibility Data

(2012) Edward P. Acosta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

(2012) Alexia Cusini et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

(2012) Marco Siccardi et al.   THERAPEUTIC DRUG MONITORING

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage

(2011) Andrea Calcagno et al.   AIDS

Current understanding of HIV-associated neurocognitive disorders pathogenesis

(2011) Patrick Gannon et al.   CURRENT OPINION IN NEUROLOGY

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study

(2011) L. Zhu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiretroviral drug treatment of CNS HIV-1 infection

(2011) A. Yilmaz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

(2010) Ana Canestri et al.   CLINICAL INFECTIOUS DISEASES

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens

(2010) D. Gonzalez de Requena et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment

(2010) Arvid Edén et al.   JOURNAL OF INFECTIOUS DISEASES

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

(2009) Aylin Yilmaz et al.   PLoS One

Low atazanavir concentrations in cerebrospinal fluid

(2008) Brookie M Best et al.   AIDS